Scroll

retinol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	2831	68-26-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vitamin A1 vitamin A retinol retinol (vit A)	Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products. Molecular weight: 286.46 Formula: C20H30O CLOGP: 6.40 LIPINSKI: 1 HAC: 1 HDO: 1 TPSA: 20.23 ALOGS: -4.58 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vitamin A1
vitamin A
retinol
retinol (vit A)

Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.

Molecular weight: 286.46
Formula: C20H30O
CLOGP: 6.40
LIPINSKI: 1
HAC: 1
HDO: 1
TPSA: 20.23
ALOGS: -4.58
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	TU	O
50	TU	P
800	U	N

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.04 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
Feb. 20, 1953	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia aspiration	237.00	15.14	112	8431	30892	50565689
Coma	168.43	15.14	110	8433	56769	50539812
Gastrooesophageal reflux disease	158.95	15.14	119	8424	76309	50520272
Blood magnesium increased	123.85	15.14	37	8506	2843	50593738
Pleural thickening	123.18	15.14	36	8507	2563	50594018
Somnolence	118.38	15.14	138	8405	154847	50441734
Presbyacusis	116.50	15.14	35	8508	2741	50593840
Pleural fibrosis	113.81	15.14	36	8507	3348	50593233
Deafness neurosensory	107.60	15.14	37	8506	4464	50592117
Epigastric discomfort	94.40	15.14	36	8507	5834	50590747
Cyst	74.95	15.14	38	8505	12149	50584432
Osteopenia	63.07	15.14	38	8505	16980	50579601
Blood potassium increased	61.77	15.14	37	8506	16361	50580220
Skin lesion	56.29	15.14	42	8501	26685	50569896
Dry eye	51.57	15.14	43	8500	32052	50564529
Bone cyst	42.08	15.14	15	8528	2009	50594572
Choanal stenosis	35.90	15.14	6	8537	27	50596554
Blood creatinine increased	35.02	15.14	53	8490	76107	50520474
Osteosclerosis	34.25	15.14	15	8528	3452	50593129
Enterobacter infection	31.87	15.14	12	8531	1876	50594705
Infective pulmonary exacerbation of cystic fibrosis	30.18	15.14	18	8525	7891	50588690
Granulomatous liver disease	29.59	15.14	9	8534	734	50595847
Osteoarthritis	27.72	15.14	45	8498	68561	50528020
Aorta hypoplasia	27.04	15.14	6	8537	139	50596442
Exostosis	26.07	15.14	19	8524	11634	50584947
Underdose	24.26	15.14	23	8520	20255	50576326
Gastrointestinal disorder	23.16	15.14	50	8493	94406	50502175
Osteochondritis	22.97	15.14	4	8539	24	50596557
Deformity	22.58	15.14	15	8528	7925	50588656
Renal impairment	22.02	15.14	43	8500	75618	50520963
Sleep disorder	19.73	15.14	35	8508	57248	50539333
Tracheo-oesophageal fistula	19.28	15.14	6	8537	528	50596053
Malabsorption	18.35	15.14	10	8533	3696	50592885
Bone hypertrophy	16.96	15.14	5	8538	366	50596215
Anomaly of external ear congenital	15.71	15.14	4	8539	169	50596412
Hiatus hernia strangulated	15.71	15.14	4	8539	169	50596412
Treatment failure	15.69	15.14	55	8488	137582	50458999
Hepatic cirrhosis	15.65	15.14	17	8526	17560	50579021
Oesophageal atresia	15.24	15.14	5	8538	522	50596059

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	55.79	17.34	22	3121	6214	29565170
Coronavirus infection	17.41	17.34	8	3135	3280	29568104
Febrile convulsion	17.35	17.34	5	3138	540	29570844

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia aspiration	185.16	13.75	113	9432	59158	64430029
Gastrooesophageal reflux disease	168.52	13.75	121	9424	83022	64406165
Coma	147.33	13.75	114	9431	87501	64401686
Somnolence	121.63	13.75	150	9395	203495	64285692
Presbyacusis	105.79	13.75	31	9514	2544	64486643
Pleural thickening	104.23	13.75	31	9514	2679	64486508
Blood magnesium increased	98.85	13.75	31	9514	3200	64485987
Pleural fibrosis	91.97	13.75	31	9514	4019	64485168
Deafness neurosensory	88.88	13.75	34	9511	6340	64482847
Epigastric discomfort	79.71	13.75	32	9513	6779	64482408
Infective pulmonary exacerbation of cystic fibrosis	74.76	13.75	36	9509	11760	64477427
Cyst	62.28	13.75	32	9513	11995	64477192
Dry eye	60.44	13.75	43	9502	28976	64460211
Osteopenia	57.25	13.75	33	9512	15507	64473680
Skin lesion	47.59	13.75	41	9504	36441	64452746
Bone cyst	42.81	13.75	15	9530	2182	64487005
Blood potassium increased	37.59	13.75	31	9514	25949	64463238
Osteosclerosis	32.74	13.75	14	9531	3472	64485715
Deformity	27.62	13.75	15	9530	6282	64482905
Osteoarthritis	24.61	13.75	38	9507	63298	64425889
Osteochondritis	23.50	13.75	4	9541	24	64489163
Sleep disorder	23.44	13.75	36	9509	59673	64429514
Cystic fibrosis	23.34	13.75	11	9534	3423	64485764
Enterobacter infection	22.57	13.75	11	9534	3685	64485502
Granulomatous liver disease	22.50	13.75	8	9537	1214	64487973
Underdose	22.12	13.75	23	9522	25806	64463381
Exostosis	21.64	13.75	16	9529	11422	64477765
Gastrointestinal disorder	20.86	13.75	43	9502	89666	64399521
Treatment failure	20.45	13.75	50	9495	116766	64372421
Completed suicide	18.79	13.75	5	9540	224409	64264778
Bone hypertrophy	18.25	13.75	5	9540	321	64488866
Vitamin A decreased	18.08	13.75	3	9542	15	64489172
Prealbumin decreased	17.37	13.75	4	9541	126	64489061
Breast cancer	16.57	13.75	21	9524	29127	64460060
Hypervitaminosis A	16.45	13.75	3	9542	28	64489159
Hiatus hernia strangulated	16.23	13.75	4	9541	169	64489018
Blood creatinine increased	15.72	13.75	50	9495	135732	64353455
Oesophageal adenocarcinoma	14.03	13.75	5	9540	764	64488423
Hospitalisation	14.02	13.75	33	9512	75174	64414013

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A11CA01	ALIMENTARY TRACT AND METABOLISM VITAMINS VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO Vitamin A, plain
ATC	D10AD02	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne
ATC	R01AX02	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Other nasal preparations
ATC	S01XA02	SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals
FDA CS	M0022788	Vitamin A
CHEBI has role	CHEBI:24020	fat-soluble vitamins
CHEBI has role	CHEBI:25212	metabolites
MeSH PA	D018977	Micronutrients
MeSH PA	D014815	Vitamins
FDA EPC	N0000175950	Vitamin A
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Vitamin A deficiency	indication	72000004
Vitamin deficiency	indication	85670002
Mineral deficiency	indication	111379007
Prevention of dental caries	indication	426482000
Mineral Deficiency Prevention	indication
Vitamin Deficiency Prevention	indication
Diaper rash	off-label use	91487003
Abetalipoproteinemia	off-label use	190787008	DOID:1386
Skin irritation	off-label use	367466007
Peptic ulcer	contraindication	13200003	DOID:750
Primary hyperoxaluria	contraindication	17901006	DOID:2977
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Gastroenteritis	contraindication	25374005	DOID:2326
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Hemosiderosis	contraindication	39011001	DOID:12119
Hemolytic anemia	contraindication	61261009	DOID:583
Hypervitaminosis A	contraindication	64559002	DOID:9972
Ulcerative colitis	contraindication	64766004	DOID:8577
Hypercalcemia	contraindication	66931009	DOID:12678
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Anemia due to enzyme deficiency	contraindication	111577008
Hb SS disease	contraindication	127040003	DOID:10923
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Diverticular disease	contraindication	397881000
Hemochromatosis	contraindication	399187006	DOID:2352
Repeated Blood Transfusions	contraindication
Malabsorption States	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.62	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
11-cis retinol dehydrogenase	Enzyme	Q92781	RDH1_HUMAN				WOMBAT-PK
Retinol dehydrogenase 12	Enzyme	Q96NR8	RDH12_HUMAN				WOMBAT-PK
Retinol dehydrogenase 13	Enzyme	Q8NBN7	RDH13_HUMAN				WOMBAT-PK
Retinol-binding protein 3	Surface antigen	P10745	RET3_HUMAN				WOMBAT-PK
Retinol-binding protein 5	Cytosolic other	P82980	RET5_HUMAN				WOMBAT-PK
Retinoid-binding protein 7	Cytosolic other	Q96R05	RET7_HUMAN				WOMBAT-PK
Retinol-binding protein 4	Secreted	P02753	RET4_HUMAN		Kd	6.74	CHEMBL
Retinol-binding protein 2	Cytosolic other	P50120	RET2_HUMAN				WOMBAT-PK
Retinal dehydrogenase 2	Enzyme	O94788	AL1A2_HUMAN				WOMBAT-PK
Retinal dehydrogenase 1	Enzyme	P00352	AL1A1_HUMAN				WOMBAT-PK
Retinaldehyde-binding protein 1	Transporter	P12271	RLBP1_HUMAN				WOMBAT-PK
Retinol-binding protein 1	Cytosolic other	P09455	RET1_HUMAN				WOMBAT-PK
Amyloid beta A4 protein	Unclassified	P05067	A4_HUMAN		IC50	6.75	CHEMBL
Nuclear receptor subfamily 2 group C member 2	Nuclear other	P49116	NR2C2_HUMAN	AGONIST	EC50	4.71	IUPHAR
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	6.72	CHEMBL
Beta-lactoglobulin	Unclassified		LACB_BOVIN		Kd	7.44	CHEMBL

External reference:

ID	Source
4021164	VUID
N0000148615	NUI
D06543	KEGG_DRUG
11103-57-4	SECONDARY_CAS_RN
4017648	VANDF
4021164	VANDF
4021715	VANDF
C0042839	UMLSCUI
CHEBI:50211	CHEBI
RTL	PDB_CHEM_ID
CHEMBL986	ChEMBL_ID
CHEMBL1675	ChEMBL_ID
DB00162	DRUGBANK_ID
D014801	MESH_DESCRIPTOR_UI
445354	PUBCHEM_CID
4053	IUPHAR_LIGAND_ID
2243	INN_ID
G2SH0XKK91	UNII
11246	RXNORM
232172	MMSL
5678	MMSL
975	MMSL
d00402	MMSL
001000	NDDF
82156005	SNOMEDCT_US
82622003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VitafolOne	HUMAN PRESCRIPTION DRUG LABEL	16	0642-0070	CAPSULE, GELATIN COATED	330 ug	ORAL	unapproved drug other	14 sections
Vitafol Caplet	HUMAN PRESCRIPTION DRUG LABEL	12	0642-0072	CAPSULE	6000 [iU]	ORAL	UNAPPROVED DRUG OTHER	13 sections
Vitafol OB Caplet	HUMAN PRESCRIPTION DRUG LABEL	15	0642-0079	TABLET	2700 [iU]	ORAL	Unapproved drug other	14 sections
Vitafol Plus	HUMAN PRESCRIPTION DRUG LABEL	17	0642-0092	CAPSULE, LIQUID FILLED	1100 [iU]	ORAL	UNAPPROVED DRUG OTHER	13 sections
Strovite Forte Caplet	HUMAN PRESCRIPTION DRUG LABEL	19	0642-0204	TABLET, COATED	4000 [iU]	ORAL	UNAPPROVED DRUG OTHER	15 sections
Strovite One Caplets	HUMAN PRESCRIPTION DRUG LABEL	20	0642-0207	TABLET	900 ug	ORAL	UNAPPROVED DRUG OTHER	14 sections
Reaphirm Plant Source DHA	HUMAN PRESCRIPTION DRUG LABEL	16	0642-3010	CAPSULE, GELATIN COATED	1100 [iU]	ORAL	unapproved drug other	7 sections
O-Cal Prenatal Vitamin	HUMAN PRESCRIPTION DRUG LABEL	16	0813-0202	TABLET	2500 [iU]	ORAL	UNAPPROVED DRUG OTHER	6 sections
Budpak Vitamin A and D	HUMAN OTC DRUG LABEL	2	27293-036	CREAM	181.80 [iU]	TOPICAL	OTC monograph not final	11 sections
Multivitamin with fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	50090-0356	TABLET, CHEWABLE	2500 [iU]	ORAL	UNAPPROVED DRUG OTHER	8 sections
Multivitamin with fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	50090-0435	TABLET, CHEWABLE	2500 [iU]	ORAL	UNAPPROVED DRUG OTHER	8 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	12	50090-4475	TABLET, CHEWABLE	750 ug	ORAL	unapproved drug other	10 sections
Multi Vitamin and Mineralvitamin	HUMAN OTC DRUG LABEL	11	51220-2001	TABLET, CHEWABLE	3.50 mg	ORAL	unapproved drug other	8 sections
Vitamin A and D	HUMAN OTC DRUG LABEL	2	52000-026	CREAM	181.80 [iU]	TOPICAL	OTC monograph not final	11 sections
Kimchi Vitaminchewable multivitamin	HUMAN OTC DRUG LABEL	11	52102-1001	TABLET, CHEWABLE	0.68 mg	ORAL	unapproved drug other	2 sections
Multi-Vitamin Fluoride Drops	HUMAN PRESCRIPTION DRUG LABEL	10	52959-593	SOLUTION	1500 [iU]	ORAL	Unapproved drug other	11 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	58657-163	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	58657-164	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	58657-165	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
M-Natal Plus	HUMAN PRESCRIPTION DRUG LABEL	14	58657-170	TABLET	4000 [iU]	ORAL	unapproved drug other	7 sections
Tri-Vite Drops with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	4	58657-323	SOLUTION	1500 [iU]	ORAL	unapproved drug other	9 sections
Tri-Vite Drops with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	4	58657-324	SOLUTION	1500 [iU]	ORAL	unapproved drug other	9 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	12	59088-107	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	12	59088-108	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	9 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	12	59088-109	TABLET, CHEWABLE	750 ug	ORAL	unapproved drug other	10 sections
INATAL ADVANCE	HUMAN PRESCRIPTION DRUG LABEL	16	63044-153	TABLET, COATED	2700 [iU]	ORAL	Unapproved drug other	11 sections
INATAL Ultra	HUMAN PRESCRIPTION DRUG LABEL	16	63044-154	TABLET, COATED	2700 [iU]	ORAL	Unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	63629-1134	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	63629-1134	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections
Multivitamin with Fluoride	HUMAN PRESCRIPTION DRUG LABEL	11	63629-1135	TABLET, CHEWABLE	2500 [iU]	ORAL	unapproved drug other	10 sections